Skip to main content

Table 3 Summary of clinical chemistry data; mean (SD), N = 8

From: Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations

Variable (reference range and units)a

Day

Group 1 (sham)

Group 2 (2 mg/kg)

Group 3 (6 mg/kg)

Group 4 (10 mg/kg)

P-value2

Treatment

Alkaline phosphatase (1–114 U/L)

Pretest

89.3 (25.9)

101.5 (21.9)

86.4 (11.5)

94.4 (16.1)

0.8687

30

76.8 (28.7)

82.9 (16.8)

70.0 (10.6)

79.3 (15.0)

91

47.9 (17.6)

53.5 (14.2)

45.1 (10.9)

50.6 (8.5)

181

36.6 (17.1)

41.8 (15.3)

36.1 (6.0)

42.1 (8.6)

Aspartate aminotransferase (28–60 U/L)

Pretest

35.1 (5.3)

35.5 (5.3)

38.1 (8.3)

36.1 (9.5)

0.7180

30

31.1 (6.8)

30.3 (6.2)

30.1 (4.0)

30.4 (3.8)

91

30.4 (5.5)

34.8 (3.8)

31.3 (5.4)

26.8 (3.5)

181

27.9 (8.6)

27.1 (5.3)

27.8 (4.7)

28.8 (3.7)

Alanine aminotransferase (10–109 U/L)

Pretest

27.6 (5.0)

28.8 (4.1)

28.4 (7.8)

28.6 (7.2)

0.8099

30

30.6 (7.1)

29.4 (5.6)

32.6 (5.8)

29.3 (3.5)

91

30.5 (6.6)

36.0 (10.1)

31.9 (5.1)

34.1 (12.9)

181

32.3 (12.8)

29.0 (7.0)

33.6 (9.5)

37.6 (12.8)

Creatine kinase (52–368 U/L)

Pretest

312.1 (153.0)

261.8 (98.7)

278.8 (52.5)

324.4 (228.5)

0.7749

30

216.5 (57.9)

186.8 (56.5)

182.1 (26.6)

211.4 (40.8)

91

185.8 (38.8)

248.3 (153.8)

182.3 (44.3)

163.8 (41.6)

181

197.1 (81.3)

174.4 (55.3)

180.9 (59.0)

179.1 (45.8)

Urea nitrogen (8–28 mg/dL)

Pretest

11.0 (2.6)

11.5 (1.6)

11.4 (2.1)

11.1 (1.9)

0.5554

30

13.8 (2.8)

13.3 (1.6)

13.4 (2.3)

13.8 (1.8)

91

15.3 (1.9)

15.0 (2.8)

14.1 (2.9)

13.0 (2.4)

181

15.1 (2.4)

15.5 (2.5)

14.3 (2.8)

15.6 (1.8)

Creatinine (0.5–1.7 mg/dL)

Pretest

0.59 (0.08)

0.60 (0.05)

0.59 (0.04)

0.58 (0.07)

0.8214

30

0.70 (0.14)

0.69 (0.06)

0.66 (0.07)

0.68 (0.07)

91

0.73 (0.10)

0.74 (0.07)

0.69 (0.08)

0.69 (0.10)

181

0.76 (0.14)

0.74 (0.09)

0.74 (0.05)

0.74 (0.07)

Total Protein (5.4–7.5 g/dL)

Pretest

5.83 (0.20)

5.56 (0.17)

5.75 (0.31)

5.68 (0.27)

0.6166

30

5.90 (0.26)

5.61 (0.11)

5.76 (0.36)

5.75 (0.25)

91

5.69 (0.16)

5.46 (0.15)

5.55 (0.40)

5.60 (0.23)

181

6.46 (0.14)

6.19 (0.14)

6.23 (0.38)

6.25 (0.30)

Albumin (2.9–3.9 g/dL)

Pretest

3.34 (0.16)

3.18 (0.12)

3.20 (0.15)

3.21 (0.10)

0.0631

30

3.24 (0.17)

3.08 (0.15)

3.09 (0.16)

3.19 (0.16)

91

3.48 (0.15)

3.35 (0.12)

3.24 (0.19)

3.36 (0.11)

181

3.64 (0.12)

3.31 (0.12)

3.31 (0.22)

3.45 (0.13)

Direct bilirubin (0.0–0.3 mg/dL)

Pretest

(−)

(−)

(−)

(−)

0.4098

30

0.00 (0.00)

0.01 (0.04)

0.00 (0.00)

0.04 (0.05)

91

0.04 (0.05)

0.00 (0.00)

0.03 (0.05)

0.00 (0.00)

181

0.01 (0.04)

0.00 (0.00)

0.01 (0.04)

0.01 (0.04)

Cholesterol (135–278 mg/dL)

Pretest

164.3 (30.1)

145.8 (24.3)

155.5 (22.5)

158.6 (23.1)

0.1893

30

156.6 (26.6)

136.5 (19.2)

142.4 (14.7)

146.0 (18.0)

91

153.1 (41.3)

131.1 (18.6)

133.9 (12.1)

147.4 (24.8)

181

194.4 (54.2)

186.1 (55.0)

177.1 (37.6)

158.0 (30.4)

Calcium (9.1–11.7 mg/dL)

Pretest

11.01 (0.33)

10.73 (0.21)

10.86 (0.26)

10.91 (0.26)

0.0423

30

11.03 (0.28)

10.93 (0.18)

10.85 (0.26)

10.99 (0.27)

91

10.54 (0.15)

10.46 (0.09)

10.30 (0.20)

10.46 (0.31)

181

10.86 (0.37)

10.74 (0.11)

10.69 (0.18)

10.88 (0.23)

  1. Footnote:
  2. a These reference ranges are to be used for information only and the pretest values collected before the dosing period during acclimatization should be used for interpretation in the context of this study
  3. 2 P-values in bold denote significance
  4. (−) Direct bilirubin was not analyzed for the pretest interval due to a protocol deviation